Samsung Bioepis Goes After Lucentis With 40% Cheaper Byooviz Launch In US
Delivers Global First With Ranibizumab Biosimilar Launch Through Partner Biogen
Samsung Bioepis and Biogen have come in with a hefty discount as they mark a major milestone by launching their Byooviz biosimilar ranibizumab rival to Lucentis in the US.
